{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:34:25Z","timestamp":1790681665895,"version":"4.1.0"},"publisher-location":"Berlin, Heidelberg","reference-count":157,"publisher":"Springer Berlin Heidelberg","isbn-type":[{"value":"9783642386633","type":"print"},{"value":"9783642386640","type":"electronic"}],"license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013]]},"DOI":"10.1007\/978-3-642-38664-0_9","type":"book-chapter","created":{"date-parts":[[2013,10,3]],"date-time":"2013-10-03T06:57:23Z","timestamp":1380783443000},"page":"199-227","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Endothelin Receptor Antagonists"],"prefix":"10.1007","author":[{"given":"Martine","family":"Clozel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Maresta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Humbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,8,6]]},"reference":[{"key":"9_CR00091","unstructured":"Actelion Pharmaceuticals Ltd. (2011) Summary of product characteristics Tracleer\u00ae. Actelion Pharmaceuticals Ltd., Allschwil, Switzerland"},{"key":"9_CR00092","unstructured":"Actelion press release, 30th April 2012"},{"issue":"1","key":"9_CR00093","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S0008-6363(97)00206-X","volume":"37","author":"M Adner","year":"1998","unstructured":"Adner M, Uddman E, Cardell LO, Edvinsson L (1998) Regional variation in appearance of vascular contractile endothelin-B receptors following organ culture. Cardiovasc Res 37(1):254\u2013262","journal-title":"Cardiovasc Res"},{"issue":"1","key":"9_CR00094","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1006\/bbrc.1998.9409","volume":"251","author":"M Akishita","year":"1998","unstructured":"Akishita M, Kozaki K, Eto M, Yoshizumi M, Ishikawa M, Toba K et al (1998) Estrogen attenuates endothelin-1 production by bovine endothelial cells via estrogen receptor. Biochem Biophys Res Commun 251(1):17\u201321","journal-title":"Biochem Biophys Res Commun"},{"issue":"15","key":"9_CR00095","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1161\/01.CIR.0000144462.08345.B9","volume":"110","author":"F Amiri","year":"2004","unstructured":"Amiri F, Virdis A, Neves MF, Iglarz M, Seidah NG, Touyz RM et al (2004) Endothelium-restricted overexpression of human endothelin-1 causes vascular remodeling and endothelial dysfunction. Circulation 110(15):2233\u20132240","journal-title":"Circulation"},{"issue":"22","key":"9_CR00096","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1161\/01.CIR.102.22.2781","volume":"102","author":"S Archer","year":"2000","unstructured":"Archer S, Rich S (2000) Primary pulmonary hypertension: a vascular biology and translational research \u201cwork in progress\u201d. Circulation 102(22):2781\u20132791","journal-title":"Circulation"},{"issue":"6","key":"9_CR00097","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1136\/hrt.2004.053991","volume":"91","author":"T Attina","year":"2005","unstructured":"Attina T, Camidge R, Newby DE, Webb DJ (2005) Endothelin antagonism in pulmonary hypertension, heart failure, and beyond. Heart 91(6):825\u2013831","journal-title":"Heart"},{"key":"9_CR00098","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1164\/rccm.200307-957OC","volume":"169","author":"RJ Barst","year":"2004","unstructured":"Barst RJ, Langleben D, Frost A et al (2004) Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 169:441\u2013447","journal-title":"Am J Respir Crit Care Med"},{"key":"9_CR00099","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/j.jacc.2006.01.057","volume":"47","author":"RJ Barst","year":"2006","unstructured":"Barst RJ, Langleben D, Badesch D et al (2006) Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 47:2049\u20132056","journal-title":"J Am Coll Cardiol"},{"key":"9_CR000910","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1159\/000328859","volume":"172","author":"M Barton","year":"2011","unstructured":"Barton M, Kohan DE (2011) Endothelin antagonists in clinical trials: lessons learned. Contrib Nephrol 172:255\u2013260","journal-title":"Contrib Nephrol"},{"issue":"6","key":"9_CR000911","first-page":"653","volume":"231","author":"B Battistini","year":"2006","unstructured":"Battistini B, Berthiaume N, Kelland NF, Webb DJ, Kohan DE (2006) Profile of past and current clinical trials involving endothelin receptor antagonists: the novel \u201c-sentan\u201d class of drug. Exp Biol Med (Maywood) 231(6):653\u2013695","journal-title":"Exp Biol Med (Maywood)"},{"issue":"9","key":"9_CR000912","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1161\/hc0902.105719","volume":"105","author":"M Bauer","year":"2002","unstructured":"Bauer M, Wilkens H, Langer F, Schneider SO, Lausberg H, Schafers HJ (2002) Selective upregulation of endothelin B receptor gene expression in severe pulmonary hypertension. Circulation 105(9):1034\u20131036","journal-title":"Circulation"},{"issue":"9","key":"9_CR000913","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1136\/gut.52.9.1355","volume":"52","author":"FS Benjaminov","year":"2003","unstructured":"Benjaminov FS, Prentice M, Sniderman KW, Siu S, Liu P, Wong F (2003) Portopulmonary hypertension in decompensated cirrhosis with refractory ascites. Gut 52(9):1355\u20131362","journal-title":"Gut"},{"issue":"4","key":"9_CR000914","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00408-008-9092-8","volume":"186","author":"RL Benza","year":"2008","unstructured":"Benza RL (2008) Pulmonary hypertension associated with sickle cell disease: pathophysiology and rationale for treatment. Lung 186(4):247\u2013254","journal-title":"Lung"},{"issue":"17","key":"9_CR0009160","doi-asserted-by":"crossref","first-page":"7849","DOI":"10.1021\/jm3009103","volume":"55","author":"MH Bolli","year":"2012","unstructured":"Bolli MH, Boss C, Binkert C et al (2012) The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N\u2019-propylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist. J Med Chem 55(17):7849\u20137861","journal-title":"J Med Chem"},{"issue":"6","key":"9_CR000915","doi-asserted-by":"crossref","first-page":"R1288","DOI":"10.1152\/ajpregu.00397.2010","volume":"300","author":"SL Bourque","year":"2011","unstructured":"Bourque SL, Davidge ST, Adams MA (2011) The interaction between endothelin-1 and nitric oxide in the vasculature: new perspectives. Am J Physiol Regul Integr Comp Physiol 300(6):R1288\u2013R1295","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"2","key":"9_CR000916","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s003950050170","volume":"95","author":"M Browatzki","year":"2000","unstructured":"Browatzki M, Schmidt J, Kubler W, Kranzhofer R (2000) Endothelin-1 induces interleukin-6 release via activation of the transcription factor NF-kappaB in human vascular smooth muscle cells. Basic Res Cardiol 95(2):98\u2013105","journal-title":"Basic Res Cardiol"},{"key":"9_CR0009151","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1208\/s12248-011-9316-3","volume":"14","author":"S Bruderer","year":"2012","unstructured":"Bruderer S, Aanismaa P, Homery MC, Hausler S, Landskroner K, Sidharta PN, Treiber A, Dingemanse J (2012a) Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist. AAPS J 14:68\u201378","journal-title":"AAPS J"},{"key":"9_CR0009152","doi-asserted-by":"crossref","first-page":"901","DOI":"10.3109\/00498254.2012.664665","volume":"42","author":"S Bruderer","year":"2012","unstructured":"Bruderer S, Hopfgartner G, Seiberling M, Wank J, Sidharta PN, Treiber A, Dingemanse J (2012b) Absorption, distribution, metabolism, and excretion of macitentan, a dual endothelin receptor antagonist, in humans. Xenobiotica 42:901","journal-title":"Xenobiotica"},{"issue":"1","key":"9_CR000917","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S0008-6363(96)00189-7","volume":"33","author":"P Cacoub","year":"1997","unstructured":"Cacoub P, Dorent R, Nataf P, Carayon A, Riquet M, Noe E et al (1997) Endothelin-1 in the lungs of patients with pulmonary hypertension. Cardiovasc Res 33(1):196\u2013200","journal-title":"Cardiovasc Res"},{"key":"9_CR000918","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1471-2466-8-20","volume":"8","author":"P Carratu","year":"2008","unstructured":"Carratu P, Scoditti C, Maniscalco M, Seccia TM, Di Gioia G, Gadaleta F et al (2008) Exhaled and arterial levels of endothelin-1 are increased and correlate with pulmonary systolic pressure in COPD with pulmonary hypertension. BMC Pulm Med 8:20","journal-title":"BMC Pulm Med"},{"issue":"3","key":"9_CR000919","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S1010-7940(99)00017-2","volume":"15","author":"JP Carteaux","year":"1999","unstructured":"Carteaux JP, Roux S, Siaghy M, Schjoth B, Dolofon P, Bechamps Y et al (1999) Acute pulmonary hypertension after cardiopulmonary bypass in pig: the role of endogenous endothelin. Eur J Cardiothorac Surg 15(3):346\u2013352","journal-title":"Eur J Cardiothorac Surg"},{"key":"9_CR000920","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0140-6736(01)06250-X","volume":"358","author":"RN Channick","year":"2001","unstructured":"Channick RN, Simonneau G, Sitbon O et al (2001) Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 358:1119\u20131123","journal-title":"Lancet"},{"issue":"6","key":"9_CR000921","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1152\/jappl.1995.79.6.2122","volume":"79","author":"SJ Chen","year":"1995","unstructured":"Chen SJ, Chen YF, Meng QC, Durand J, Dicarlo VS, Oparil S (1995) Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats. J Appl Physiol 79(6):2122\u20132131","journal-title":"J Appl Physiol"},{"issue":"6","key":"9_CR000922","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/00005344-199706000-00003","volume":"29","author":"SJ Chen","year":"1997","unstructured":"Chen SJ, Chen YF, Opgenorth TJ, Wessale JL, Meng QC, Durand J et al (1997) The orally active nonpeptide endothelin A-receptor antagonist A-127722 prevents and reverses hypoxia-induced pulmonary hypertension and pulmonary vascular remodeling in Sprague-Dawley rats. J Cardiovasc Pharmacol 29(6):713\u2013725","journal-title":"J Cardiovasc Pharmacol"},{"key":"9_CR000923","unstructured":"ClinicalTrials.gov. Study of ACT-064992 on morbidity and mortality in patients with symptomatic pulmonary arterial hypertension. NCT00660179 [updated July 26, 2012]"},{"issue":"11","key":"9_CR000924","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/ddr.20156","volume":"67","author":"M Clozel","year":"2006","unstructured":"Clozel M, Flores S (2006) Endothelin receptors as drug targets in chronic cardiovascular diseases: the rationale for dual antagonism. Drug Dev Res 67(11):825\u2013834","journal-title":"Drug Dev Res"},{"issue":"Suppl 3","key":"9_CR000925","doi-asserted-by":"crossref","first-page":"S262","DOI":"10.1097\/00005344-199506263-00079","volume":"26","author":"M Clozel","year":"1995","unstructured":"Clozel M, Gray GA (1995) Are there different ETB receptors mediating constriction and relaxation? J Cardiovasc Pharmacol 26(Suppl 3):S262\u2013S264","journal-title":"J Cardiovasc Pharmacol"},{"issue":"2","key":"9_CR000926","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/0006-291X(92)90826-7","volume":"186","author":"M Clozel","year":"1992","unstructured":"Clozel M, Gray GA, Breu V, Loffler BM, Osterwalder R (1992) The endothelin ETB receptor mediates both vasodilation and vasoconstriction in vivo. Biochem Biophys Res Commun 186(2):867\u2013873","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"9_CR000927","first-page":"967","volume":"231","author":"M Clozel","year":"2006","unstructured":"Clozel M, Hess P, Rey M, Iglarz M, Binkert C, Qiu C (2006) Bosentan, sildenafil, and their combination in the monocrotaline model of pulmonary hypertension in rats. Exp Biol Med (Maywood) 231(6):967\u2013973","journal-title":"Exp Biol Med (Maywood)"},{"issue":"3","key":"9_CR000928","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJM198401193100304","volume":"310","author":"RG Crystal","year":"1984","unstructured":"Crystal RG, Bitterman PB, Rennard SI, Hance AJ, Keogh BA (1984) Interstitial lung diseases of unknown cause. Disorders characterized by chronic inflammation of the lower respiratory tract (first of two parts). N Engl J Med 310(3):154\u2013166","journal-title":"N Engl J Med"},{"issue":"1","key":"9_CR000929","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/00005344-199601000-00023","volume":"27","author":"PH Dagassan","year":"1996","unstructured":"Dagassan PH, Breu V, Clozel M, Kunzli A, Vogt P, Turina M et al (1996) Up-regulation of endothelin-B receptors in atherosclerotic human coronary arteries. J Cardiovasc Pharmacol 27(1):147\u2013153","journal-title":"J Cardiovasc Pharmacol"},{"issue":"2","key":"9_CR000930","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1124\/pr.54.2.219","volume":"54","author":"AP Davenport","year":"2002","unstructured":"Davenport AP (2002) International Union of Pharmacology. XXIX. Update on endothelin receptor nomenclature. Pharmacol Rev 54(2):219\u2013226","journal-title":"Pharmacol Rev"},{"key":"9_CR000931","doi-asserted-by":"crossref","unstructured":"Davenport AP, Maguire JJ (2006) Endothelin. Handb Exp Pharmacol (176 Pt 1):295\u2013329","DOI":"10.1007\/3-540-32967-6_9"},{"issue":"3","key":"9_CR000932","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1164\/ajrccm.165.3.2104059","volume":"165","author":"N Davie","year":"2002","unstructured":"Davie N, Haleen SJ, Upton PD, Polak JM, Yacoub MH, Morrell NW et al (2002) ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am J Respir Crit Care Med 165(3):398\u2013405","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"9_CR000933","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.2353\/ajpath.2006.050754","volume":"168","author":"NJ Davie","year":"2006","unstructured":"Davie NJ, Gerasimovskaya EV, Hofmeister SE, Richman AP, Jones PL, Reeves JT et al (2006) Pulmonary artery adventitial fibroblasts cooperate with vasa vasorum endothelial cells to regulate vasa vasorum neovascularization: a process mediated by hypoxia and endothelin-1. Am J Pathol 168(6):1793\u20131807","journal-title":"Am J Pathol"},{"issue":"5 Pt 1","key":"9_CR000934","first-page":"L690","volume":"269","author":"VS DiCarlo","year":"1995","unstructured":"DiCarlo VS, Chen SJ, Meng QC, Durand J, Yano M, Chen YF et al (1995) ETA-receptor antagonist prevents and reverses chronic hypoxia-induced pulmonary hypertension in rat. Am J Physiol 269(5 Pt 1):L690\u2013L697","journal-title":"Am J Physiol"},{"key":"9_CR000935","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1471-2261-9-40","volume":"9","author":"I Dimitrijevic","year":"2009","unstructured":"Dimitrijevic I, Edvinsson ML, Chen Q, Malmsjo M, Kimblad PO, Edvinsson L (2009) Increased expression of vascular endothelin type B and angiotensin type 1 receptors in patients with ischemic heart disease. BMC Cardiovasc Disord 9:40","journal-title":"BMC Cardiovasc Disord"},{"issue":"4","key":"9_CR000936","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1152\/jappl.1996.81.4.1510","volume":"81","author":"J Dupuis","year":"1996","unstructured":"Dupuis J, Goresky CA, Fournier A (1996a) Pulmonary clearance of circulating endothelin-1 in dogs in vivo: exclusive role of ETB receptors. J Appl Physiol 81(4):1510\u20131515","journal-title":"J Appl Physiol"},{"issue":"7","key":"9_CR000937","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1161\/01.CIR.94.7.1578","volume":"94","author":"J Dupuis","year":"1996","unstructured":"Dupuis J, Stewart DJ, Cernacek P, Gosselin G (1996b) Human pulmonary circulation is an important site for both clearance and production of endothelin-1. Circulation 94(7):1578\u20131584","journal-title":"Circulation"},{"issue":"2 Pt 2","key":"9_CR000938","first-page":"H828","volume":"268","author":"S Eddahibi","year":"1995","unstructured":"Eddahibi S, Raffestin B, Clozel M, Levame M, Adnot S (1995) Protection from pulmonary hypertension with an orally active endothelin receptor antagonist in hypoxic rats. Am J Physiol 268(2 Pt 2):H828\u2013H835","journal-title":"Am J Physiol"},{"issue":"6","key":"9_CR000939","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1084\/jem.172.6.1741","volume":"172","author":"H Ehrenreich","year":"1990","unstructured":"Ehrenreich H, Anderson RW, Fox CH, Rieckmann P, Hoffman GS, Travis WD et al (1990) Endothelins, peptides with potent vasoactive properties, are produced by human macrophages. J Exp Med 172(6):1741\u20131748","journal-title":"J Exp Med"},{"issue":"6","key":"9_CR000940","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1210\/endo.133.6.8243267","volume":"133","author":"T Emori","year":"1993","unstructured":"Emori T, Hirata Y, Imai T, Eguchi S, Kanno K, Marumo F (1993) Cellular mechanism of natriuretic peptides-induced inhibition of endothelin-1 biosynthesis in rat endothelial cells. Endocrinology 133(6):2474\u20132480","journal-title":"Endocrinology"},{"issue":"4","key":"9_CR000941","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1067\/mcp.2001.114667","volume":"69","author":"K Fattinger","year":"2001","unstructured":"Fattinger K, Funk C, Pantze M, Weber C, Reichen J, Stieger B et al (2001) The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther 69(4):223\u2013231","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"9_CR000942","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1476-5381.1995.tb15868.x","volume":"115","author":"JG Filep","year":"1995","unstructured":"Filep JG, Fournier A, Foldes-Filep E (1995) Acute pro-inflammatory actions of endothelin-1 in the guinea-pig lung: involvement of ETA and ETB receptors. Br J Pharmacol 115(2):227\u2013236","journal-title":"Br J Pharmacol"},{"issue":"3","key":"9_CR000943","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1172\/JCI115915","volume":"90","author":"JD Firth","year":"1992","unstructured":"Firth JD, Ratcliffe PJ (1992) Organ distribution of the three rat endothelin messenger RNAs and the effects of ischemia on renal gene expression. J Clin Invest 90(3):1023\u20131031","journal-title":"J Clin Invest"},{"issue":"11","key":"9_CR000944","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1093\/cvr\/28.11.1613","volume":"28","author":"C Frelin","year":"1994","unstructured":"Frelin C, Guedin D (1994) Why are circulating concentrations of endothelin-1 so low? Cardiovasc Res 28(11):1613\u20131622","journal-title":"Cardiovasc Res"},{"issue":"6","key":"9_CR000945","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1111\/j.1476-5381.1996.tb16688.x","volume":"117","author":"T Fukuroda","year":"1996","unstructured":"Fukuroda T, Ozaki S, Ihara M, Ishikawa K, Yano M, Miyauchi T et al (1996) Necessity of dual blockade of endothelin ETA and ETB receptor subtypes for antagonism of endothelin-1-induced contraction in human bronchi. Br J Pharmacol 117(6):995\u2013999","journal-title":"Br J Pharmacol"},{"key":"9_CR000946","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1161\/CIRCULATIONAHA.106.630715","volume":"114","author":"N Gali\u00e8","year":"2006","unstructured":"Gali\u00e8 N, Beghetti M, Gatzoulis MA et al (2006) Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 114:48\u201354","journal-title":"Circulation"},{"key":"9_CR000947","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1161\/CIRCULATIONAHA.107.742510","volume":"117","author":"N Gali\u00e8","year":"2008","unstructured":"Gali\u00e8 N, Olschewski H, Oudiz RJ et al (2008) Ambrisentan for the treatment of pulmonary arterial hypertension. Circulation 117:3010\u20133019","journal-title":"Circulation"},{"issue":"2","key":"9_CR000949","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1183\/09031936.00194810","volume":"37","author":"N Galie","year":"2011","unstructured":"Galie N, Hoeper MM, Gibbs JS, Simonneau G (2011) Liver toxicity of sitaxentan in pulmonary arterial hypertension. Eur Respir J 37(2):475\u2013476","journal-title":"Eur Respir J"},{"issue":"4","key":"9_CR000950","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/jcb.20608","volume":"96","author":"L Gallelli","year":"2005","unstructured":"Gallelli L, Pelaia G, D\u2019Agostino B, Cuda G, Vatrella A, Fratto D et al (2005) Endothelin-1 induces proliferation of human lung fibroblasts and IL-11 secretion through an ET(A) receptor-dependent activation of MAP kinases. J Cell Biochem 96(4):858\u2013868","journal-title":"J Cell Biochem"},{"key":"9_CR0009153","doi-asserted-by":"crossref","first-page":"e47662","DOI":"10.1371\/journal.pone.0047662","volume":"7","author":"J Gatfield","year":"2012","unstructured":"Gatfield J, Mueller Grandjean C, Sasse T, Clozel M, Nayler O (2012) Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells. PLoS One 7:e47662","journal-title":"PLoS One"},{"key":"9_CR000951","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1056\/NEJM199306173282402","volume":"328","author":"A Giaid","year":"1993","unstructured":"Giaid A, Yanagisawa M, Langleben D, Michell RP, Levy R, Shennib H et al (1993) Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 328:1732\u20131739","journal-title":"N Engl J Med"},{"key":"9_CR000952","unstructured":"Gilead Sciences, Inc. (2011) Prescribing Information Letairis\u00ae. Gilead Sciences, Inc., Foster City, CA, USA"},{"issue":"3","key":"9_CR000953","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/01.HYP.0000028980.24709.68","volume":"40","author":"J Goddard","year":"2002","unstructured":"Goddard J, Webb DJ (2002) Endothelin antagonists and hypertension: a question of dose? Hypertension 40(3):e1\u2013e2, author reply e1\u2013e2","journal-title":"Hypertension"},{"issue":"1 Suppl","key":"9_CR000954","doi-asserted-by":"crossref","first-page":"63S","DOI":"10.1378\/chest.114.1_Supplement.63S","volume":"114","author":"CG Golden","year":"1998","unstructured":"Golden CG, Nick HS, Visner GA (1998) Thrombin regulation of endothelin-1 gene in isolated human pulmonary endothelial cells. Chest 114(1 Suppl):63S\u201364S","journal-title":"Chest"},{"issue":"8","key":"9_CR000955","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1038\/sj.bjp.0703503","volume":"130","author":"GA Gray","year":"2000","unstructured":"Gray GA, Mickley EJ, Webb DJ, McEwan PE (2000) Localization and function of ET-1 and ET receptors in small arteries post-myocardial infarction: upregulation of smooth muscle ET(B) receptors that modulate contraction. Br J Pharmacol 130(8):1735\u20131744","journal-title":"Br J Pharmacol"},{"issue":"Suppl 1","key":"9_CR000956","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1097\/01.fjc.0000166218.35168.79","volume":"44","author":"B Gregan","year":"2004","unstructured":"Gregan B, Schaefer M, Rosenthal W, Oksche A (2004) Fluorescence resonance energy transfer analysis reveals the existence of endothelin-A and endothelin-B receptor homodimers. J Cardiovasc Pharmacol 44(Suppl 1):S30\u2013S33","journal-title":"J Cardiovasc Pharmacol"},{"issue":"6","key":"9_CR000957","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1139\/Y10-060","volume":"88","author":"JC Hartman","year":"2010","unstructured":"Hartman JC, Brouwer K, Mandagere A, Melvin L, Gorczynski R (2010) Evaluation of the endothelin receptor antagonists ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwich-cultured human hepatocytes. Can J Physiol Pharmacol 88(6):682\u2013691","journal-title":"Can J Physiol Pharmacol"},{"issue":"4 Pt 1","key":"9_CR000958","first-page":"L538","volume":"271","author":"E Helset","year":"1996","unstructured":"Helset E, Lindal S, Olsen R, Myklebust R, Jorgensen L (1996) Endothelin-1 causes sequential trapping of platelets and neutrophils in pulmonary microcirculation in rats. Am J Physiol 271(4 Pt 1):L538\u2013L546","journal-title":"Am J Physiol"},{"issue":"4","key":"9_CR000959","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1152\/jappl.1997.83.4.1209","volume":"83","author":"NS Hill","year":"1997","unstructured":"Hill NS, Warburton RR, Pietras L, Klinger JR (1997) Nonspecific endothelin-receptor antagonist blunts monocrotaline-induced pulmonary hypertension in rats. J Appl Physiol 83(4):1209\u20131215","journal-title":"J Appl Physiol"},{"issue":"4","key":"9_CR000960","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1172\/JCI116338","volume":"91","author":"Y Hirata","year":"1993","unstructured":"Hirata Y, Emori T, Eguchi S, Kanno K, Imai T, Ohta K et al (1993) Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells. J Clin Invest 91(4):1367\u20131373","journal-title":"J Clin Invest"},{"issue":"4","key":"9_CR000961","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S0022-5223(96)70088-0","volume":"112","author":"P Holm","year":"1996","unstructured":"Holm P, Liska J, Clozel M, Franco-Cereceda A (1996) The endothelin antagonist bosentan: hemodynamic effects during normoxia and hypoxic pulmonary hypertension in pigs. J Thorac Cardiovasc Surg 112(4):890\u2013897","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"1\u20132","key":"9_CR000962","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/0014-5793(91)80007-P","volume":"287","author":"K Hosoda","year":"1991","unstructured":"Hosoda K, Nakao K, Hiroshi A, Suga S, Ogawa Y, Mukoyama M et al (1991) Cloning and expression of human endothelin-1 receptor cDNA. FEBS Lett 287(1\u20132):23\u201326","journal-title":"FEBS Lett"},{"key":"9_CR000963","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1183\/09031936.00138706","volume":"30","author":"M Humbert","year":"2007","unstructured":"Humbert M, Seagal ES, Kiely DG, Carlsen J, Schwerin B, Hoeper MM (2007) Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur Resp J 30:338\u2013344","journal-title":"Eur Resp J"},{"issue":"6","key":"9_CR000964","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1097\/FJC.0b013e31813c6cc3","volume":"50","author":"M Iglarz","year":"2007","unstructured":"Iglarz M, Clozel M (2007) Mechanisms of ET-1-induced endothelial dysfunction. J Cardiovasc Pharmacol 50(6):621\u2013628","journal-title":"J Cardiovasc Pharmacol"},{"issue":"11","key":"9_CR000965","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1042\/CS20100222","volume":"119","author":"M Iglarz","year":"2010","unstructured":"Iglarz M, Clozel M (2010) At the heart of tissue: endothelin system and end-organ damage. Clin Sci (Lond) 119(11):453\u2013463","journal-title":"Clin Sci (Lond)."},{"issue":"3","key":"9_CR000966","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1124\/jpet.108.142976","volume":"327","author":"M Iglarz","year":"2008","unstructured":"Iglarz M, Binkert C, Morrison K, Fischli W, Gatfield J, Treiber A et al (2008) Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther 327(3):736\u2013745","journal-title":"J Pharmacol Exp Ther"},{"key":"9_CR000967","first-page":"A6445","volume":"183","author":"M Iglarz","year":"2011","unstructured":"Iglarz M, Landskroner K, Rey M, Wanner D, Hess P, Clozel M (2011) Optimization of tissue targeting properties of macitentan, a new dual endothelin receptor antagonist, improves its efficacy in a rat model of pulmonary fibrosis associated with pulmonary arterial hypertension. Am J Respir Crit Care Med 183:A6445","journal-title":"Am J Respir Crit Care Med"},{"issue":"Suppl 56","key":"9_CR0009150","first-page":"717s","volume":"40","author":"M Iglarz","year":"2012","unstructured":"Iglarz M, Rey M, Hess P, Kauser K, Clozel M (2012) Superior in vivo efficacy of macitentan: comparison to other endothelin receptor antagonists. Eur Respir J 40(Suppl 56):717s","journal-title":"Eur Respir J"},{"issue":"6 Pt 2","key":"9_CR000968","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1161\/01.HYP.19.6.753","volume":"19","author":"T Imai","year":"1992","unstructured":"Imai T, Hirata Y, Emori T, Yanagisawa M, Masaki T, Marumo F (1992) Induction of endothelin-1 gene by angiotensin and vasopressin in endothelial cells. Hypertension 19(6 Pt 2):753\u2013757","journal-title":"Hypertension"},{"issue":"8","key":"9_CR000969","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1073\/pnas.86.8.2863","volume":"86","author":"A Inoue","year":"1989","unstructured":"Inoue A, Yanagisawa M, Kimura S, Kasuya Y, Miyauchi T, Goto K et al (1989) The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA 86(8):2863\u20132867","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"9_CR000970","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1172\/JCI116579","volume":"92","author":"H Ito","year":"1993","unstructured":"Ito H, Hirata Y, Adachi S, Tanaka M, Tsujino M, Koike A et al (1993) Endothelin-1 is an autocrine\/paracrine factor in the mechanism of angiotensin II-induced hypertrophy in cultured rat cardiomyocytes. J Clin Invest 92(1):398\u2013403","journal-title":"J Clin Invest"},{"issue":"3","key":"9_CR000971","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1203\/01.pdr.0000233056.37254.0b","volume":"60","author":"RP Jankov","year":"2006","unstructured":"Jankov RP, Kantores C, Belcastro R, Yi M, Tanswell AK (2006) Endothelin-1 inhibits apoptosis of pulmonary arterial smooth muscle in the neonatal rat. Pediatr Res 60(3):245\u2013251","journal-title":"Pediatr Res"},{"issue":"2","key":"9_CR000972","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1161\/01.CIR.103.2.314","volume":"103","author":"JF Jasmin","year":"2001","unstructured":"Jasmin JF, Lucas M, Cernacek P, Dupuis J (2001) Effectiveness of a nonselective ET(A\/B) and a selective ET(A) antagonist in rats with monocrotaline-induced pulmonary hypertension. Circulation 103(2):314\u2013318","journal-title":"Circulation"},{"issue":"7","key":"9_CR000973","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/ard.50.7.526-c","volume":"50","author":"H Julkunen","year":"1991","unstructured":"Julkunen H, Saijonmaa O, Gronhagen-Riska C, Teppo AM, Fyhrquist F (1991) Raised plasma concentrations of endothelin-1 in systemic lupus erythematosus. Ann Rheum Dis 50(7):526\u2013527","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"9_CR000974","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1161\/01.CIR.99.9.1242","volume":"99","author":"M Kakoki","year":"1999","unstructured":"Kakoki M, Hirata Y, Hayakawa H, Tojo A, Nagata D, Suzuki E et al (1999) Effects of hypertension, diabetes mellitus, and hypercholesterolemia on endothelin type B receptor-mediated nitric oxide release from rat kidney. Circulation 99(9):1242\u20131248","journal-title":"Circulation"},{"key":"9_CR000975","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1146\/annurev.pharmtox.41.1.851","volume":"41","author":"RM Kedzierski","year":"2001","unstructured":"Kedzierski RM, Yanagisawa M (2001) Endothelin system: the double-edged sword in health and disease. Annu Rev Pharmacol Toxicol 41:851\u2013876","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"4","key":"9_CR000976","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1034\/j.1399-3003.2000.15d04.x","volume":"15","author":"H Kim","year":"2000","unstructured":"Kim H, Yung GL, Marsh JJ, Konopka RG, Pedersen CA, Chiles PG et al (2000) Endothelin mediates pulmonary vascular remodelling in a canine model of chronic embolic pulmonary hypertension. Eur Respir J 15(4):640\u2013648","journal-title":"Eur Respir J"},{"issue":"1","key":"9_CR000977","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0272-6386(97)90004-4","volume":"29","author":"DE Kohan","year":"1997","unstructured":"Kohan DE (1997) Endothelins in the normal and diseased kidney. Am J Kidney Dis 29(1):2\u201326","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"9_CR000978","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1681\/ASN.2010080869","volume":"22","author":"DE Kohan","year":"2011","unstructured":"Kohan DE, Pritchett Y, Molitch M, Wen S, Garimella T, Audhya P et al (2011) Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy. J Am Soc Nephrol 22(4):763\u2013772","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"9_CR000979","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1165\/rcmb.2008-0447OC","volume":"41","author":"P Kulasekaran","year":"2009","unstructured":"Kulasekaran P, Scavone CA, Rogers DS, Arenberg DA, Thannickal VJ, Horowitz JC (2009) Endothelin-1 and transforming growth factor-beta1 independently induce fibroblast resistance to apoptosis via AKT activation. Am J Respir Cell Mol Biol 41(4):484\u2013493","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"18","key":"9_CR000980","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1093\/eurheartj\/ehq226","volume":"31","author":"P Kumpers","year":"2010","unstructured":"Kumpers P, Nickel N, Lukasz A, Golpon H, Westerkamp V, Olsson KM et al (2010) Circulating angiopoietins in idiopathic pulmonary arterial hypertension. Eur Heart J 31(18):2291\u20132300","journal-title":"Eur Heart J"},{"issue":"3","key":"9_CR000981","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1378\/chest.129.3.689","volume":"129","author":"D Langleben","year":"2006","unstructured":"Langleben D, Dupuis J, Langleben I, Hirsch AM, Baron M, Senecal JL et al (2006) Etiology-specific endothelin-1 clearance in human precapillary pulmonary hypertension. Chest 129(3):689\u2013695","journal-title":"Chest"},{"issue":"2","key":"9_CR000982","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1042\/cs0900091","volume":"90","author":"JJ Liu","year":"1996","unstructured":"Liu JJ, Chen JR, Buxton BF (1996) Unique response of human arteries to endothelin B receptor agonist and antagonist. Clin Sci (Lond) 90(2):91\u201396","journal-title":"Clin Sci (Lond)"},{"issue":"3","key":"9_CR000983","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1124\/jpet.105.091728","volume":"315","author":"ED Loomis","year":"2005","unstructured":"Loomis ED, Sullivan JC, Osmond DA, Pollock DM, Pollock JS (2005) Endothelin mediates superoxide production and vasoconstriction through activation of NADPH oxidase and uncoupled nitric-oxide synthase in the rat aorta. J Pharmacol Exp Ther 315(3):1058\u20131064","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"9_CR000984","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1097\/00005344-199405000-00022","volume":"23","author":"MR MacLean","year":"1994","unstructured":"MacLean MR, McCulloch KM, Baird M (1994) Endothelin ETA- and ETB-receptor-mediated vasoconstriction in rat pulmonary arteries and arterioles. J Cardiovasc Pharmacol 23(5):838\u2013845","journal-title":"J Cardiovasc Pharmacol"},{"issue":"1","key":"9_CR000985","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/bdd.527","volume":"28","author":"Y Mano","year":"2007","unstructured":"Mano Y, Usui T, Kamimura H (2007) Effects of bosentan, an endothelin receptor antagonist, on bile salt export pump and multidrug resistance-associated protein 2. Biopharm Drug Dispos 28(1):13\u201318","journal-title":"Biopharm Drug Dispos"},{"issue":"1","key":"9_CR000986","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S0008-6363(00)00221-2","volume":"49","author":"BA Markewitz","year":"2001","unstructured":"Markewitz BA, Farrukh IS, Chen Y, Li Y, Michael JR (2001) Regulation of endothelin-1 synthesis in human pulmonary arterial smooth muscle cells. Effects of transforming growth factor-beta and hypoxia. Cardiovasc Res 49(1):200\u2013206","journal-title":"Cardiovasc Res"},{"issue":"1","key":"9_CR000987","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/0006-291X(89)91684-7","volume":"164","author":"H Matsumoto","year":"1989","unstructured":"Matsumoto H, Suzuki N, Onda H, Fujino M (1989) Abundance of endothelin-3 in rat intestine, pituitary gland and brain. Biochem Biophys Res Commun 164(1):74\u201380","journal-title":"Biochem Biophys Res Commun"},{"key":"9_CR000988","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1183\/09031936.05.00054804","volume":"25","author":"VV McLaughlin","year":"2005","unstructured":"McLaughlin VV, Sitbon O, Badesch DB et al (2005) Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 25:244\u2013249","journal-title":"Eur Respir J"},{"issue":"7","key":"9_CR000989","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1111\/j.1476-5381.2010.00979.x","volume":"161","author":"J Milara","year":"2010","unstructured":"Milara J, Ortiz JL, Juan G, Guijarro R, Almudever P, Martorell M et al (2010) Cigarette smoke exposure up-regulates endothelin receptor B in human pulmonary artery endothelial cells: molecular and functional consequences. Br J Pharmacol 161(7):1599\u20131615","journal-title":"Br J Pharmacol"},{"issue":"5","key":"9_CR000990","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1161\/01.RES.73.5.887","volume":"73","author":"T Miyauchi","year":"1993","unstructured":"Miyauchi T, Yorikane R, Sakai S, Sakurai T, Okada M, Nishikibe M et al (1993) Contribution of endogenous endothelin-1 to the progression of cardiopulmonary alterations in rats with monocrotaline-induced pulmonary hypertension. Circ Res 73(5):887\u2013897","journal-title":"Circ Res"},{"issue":"2 Pt 2","key":"9_CR000991","first-page":"H686","volume":"269","author":"L Morbidelli","year":"1995","unstructured":"Morbidelli L, Orlando C, Maggi CA, Ledda F, Ziche M (1995) Proliferation and migration of endothelial cells is promoted by endothelins via activation of ETB receptors. Am J Physiol 269(2 Pt 2):H686\u2013H695","journal-title":"Am J Physiol"},{"issue":"3","key":"9_CR000992","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1203\/00006450-198903000-00005","volume":"25","author":"FC Morin 3rd","year":"1989","unstructured":"Morin FC 3rd (1989) Ligating the ductus arteriosus before birth causes persistent pulmonary hypertension in the newborn lamb. Pediatr Res 25(3):245\u2013250","journal-title":"Pediatr Res"},{"issue":"2\u20133","key":"9_CR000993","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1006\/pupt.1998.0142","volume":"11","author":"SE Mutsaers","year":"1998","unstructured":"Mutsaers SE, Marshall RP, Goldsack NR, Laurent GJ, McAnulty RJ (1998) Effect of endothelin receptor antagonists (BQ-485, Ro 47-0203) on collagen deposition during the development of bleomycin-induced pulmonary fibrosis in rats. Pulm Pharmacol Ther 11(2\u20133):221\u2013225","journal-title":"Pulm Pharmacol Ther"},{"issue":"2","key":"9_CR000994","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/00005344-200408000-00007","volume":"44","author":"M Nishida","year":"2004","unstructured":"Nishida M, Eshiro K, Okada Y, Takaoka M, Matsumura Y (2004) Roles of endothelin ETA and ETB receptors in the pathogenesis of monocrotaline-induced pulmonary hypertension. J Cardiovasc Pharmacol 44(2):187\u2013191","journal-title":"J Cardiovasc Pharmacol"},{"issue":"7","key":"9_CR000995","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/0735-1097(95)00399-1","volume":"26","author":"M Nootens","year":"1995","unstructured":"Nootens M, Kaufmann E, Rector T, Toher C, Judd D, Francis GS et al (1995) Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: relation to hemodynamic variables and endothelin levels. J Am Coll Cardiol 26(7):1581\u20131585","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"9_CR000996","doi-asserted-by":"crossref","first-page":"L857","DOI":"10.1152\/ajplung.00258.2011","volume":"302","author":"N Olave","year":"2012","unstructured":"Olave N, Nicola T, Zhang W, Bulger A, James ML, Oparil S et al (2012) Transforming growth factor-beta regulates endothelin-1 signaling in the newborn mouse lung during hypoxia exposure. Am J Physiol Lung Cell Mol Physiol 302(9):L857\u2013L865","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"1 Pt 1","key":"9_CR000997","first-page":"L95","volume":"268","author":"S Oparil","year":"1995","unstructured":"Oparil S, Chen SJ, Meng QC, Elton TS, Yano M, Chen YF (1995) Endothelin-A receptor antagonist prevents acute hypoxia-induced pulmonary hypertension in the rat. Am J Physiol 268(1 Pt 1):L95\u2013L100","journal-title":"Am J Physiol"},{"issue":"21","key":"9_CR000998","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1016\/j.jacc.2009.07.033","volume":"54","author":"RJ Oudiz","year":"2009","unstructured":"Oudiz RJ, Galie N, Olschewski H, Torres F, Frost A, Ghofrani HA et al (2009) Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol 54(21):1971\u20131981","journal-title":"J Am Coll Cardiol"},{"issue":"2 Pt 1","key":"9_CR000999","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1164\/ajrccm.156.2.9607123","volume":"156","author":"SH Park","year":"1997","unstructured":"Park SH, Saleh D, Giaid A, Michel RP (1997) Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist. Am J Respir Crit Care Med 156(2 Pt 1):600\u2013608","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"9_CR0009100","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1165\/ajrcmb\/7.5.492","volume":"7","author":"AJ Peacock","year":"1992","unstructured":"Peacock AJ, Dawes KE, Shock A, Gray AJ, Reeves JT, Laurent GJ (1992) Endothelin-1 and endothelin-3 induce chemotaxis and replication of pulmonary artery fibroblasts. Am J Respir Cell Mol Biol 7(5):492\u2013499","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"5","key":"9_CR0009101","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1016\/S0003-4975(99)00988-1","volume":"68","author":"JM Pearl","year":"1999","unstructured":"Pearl JM, Wellmann SA, McNamara JL, Lombardi JP, Wagner CJ, Raake JL et al (1999) Bosentan prevents hypoxia-reoxygenation-induced pulmonary hypertension and improves pulmonary function. Ann Thorac Surg 68(5):1714\u20131721, discussion 21\u201322","journal-title":"Ann Thorac Surg"},{"issue":"3","key":"9_CR0009102","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/S0022-3565(24)36925-3","volume":"282","author":"S Prie","year":"1997","unstructured":"Prie S, Leung TK, Cernacek P, Ryan JW, Dupuis J (1997) The orally active ET(A) receptor antagonist (+)-(S)-2-(4,6-dimethoxy-pyrimidin-2-yloxy)-3-methoxy-3,3-diphe nyl-propionic acid (LU 135252) prevents the development of pulmonary hypertension and endothelial metabolic dysfunction in monocrotaline-treated rats. J Pharmacol Exp Ther 282(3):1312\u20131318","journal-title":"J Pharmacol Exp Ther"},{"issue":"16","key":"9_CR0009103","doi-asserted-by":"crossref","first-page":"11938","DOI":"10.1016\/S0021-9258(17)32663-7","volume":"269","author":"BA Prins","year":"1994","unstructured":"Prins BA, Hu RM, Nazario B, Pedram A, Frank HJ, Weber MA et al (1994) Prostaglandin E2 and prostacyclin inhibit the production and secretion of endothelin from cultured endothelial cells. J Biol Chem 269(16):11938\u201311944","journal-title":"J Biol Chem"},{"key":"9_CR0009155","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1213917","volume":"369","author":"T Pulido","year":"2013","unstructured":"Pulido T, Adzerikho I, Channick RN et al (2013) Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 369:809\u2013818","journal-title":"N Engl J Med"},{"issue":"5","key":"9_CR0009104","first-page":"e65","volume":"28","author":"SG Raja","year":"2010","unstructured":"Raja SG (2010a) Endothelin receptor antagonists for pulmonary arterial hypertension: an overview. Cardiovasc Ther 28(5):e65\u2013e71","journal-title":"Cardiovasc Ther"},{"issue":"9","key":"9_CR0009105","first-page":"1066","volume":"11","author":"SG Raja","year":"2010","unstructured":"Raja SG (2010b) Macitentan, a tissue-targeting endothelin receptor antagonist for the potential oral treatment of pulmonary arterial hypertension and idiopathic pulmonary fibrosis. Curr Opin Investig Drugs 11(9):1066\u20131073","journal-title":"Curr Opin Investig Drugs"},{"issue":"3","key":"9_CR0009106","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/0006-291X(90)91989-6","volume":"169","author":"H Rakugi","year":"1990","unstructured":"Rakugi H, Tabuchi Y, Nakamaru M, Nagano M, Higashimori K, Mikami H et al (1990) Evidence for endothelin-1 release from resistance vessels of rats in response to hypoxia. Biochem Biophys Res Commun 169(3):973\u2013977","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"9_CR0009107","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1007\/BF00180042","volume":"72","author":"B Rolinski","year":"1994","unstructured":"Rolinski B, Geier SA, Sadri I, Klauss V, Bogner JR, Ehrenreich H et al (1994) Endothelin-1 immunoreactivity in plasma is elevated in HIV-1 infected patients with retinal microangiopathic syndrome. Clin Investig 72(4):288\u2013293","journal-title":"Clin Investig"},{"issue":"4\u20135","key":"9_CR0009108","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/s150100050020","volume":"27","author":"B Rolinski","year":"1999","unstructured":"Rolinski B, Heigermoser A, Lederer E, Bogner JR, Loch O, Goebel FD (1999) Endothelin-1 is elevated in the cerebrospinal fluid of HIV-infected patients with encephalopathy. Infection 27(4\u20135):244\u2013247","journal-title":"Infection"},{"issue":"9","key":"9_CR0009109","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1161\/01.CIR.0000053443.27512.33","volume":"107","author":"B Rondelet","year":"2003","unstructured":"Rondelet B, Kerbaul F, Motte S, van Beneden R, Remmelink M, Brimioulle S et al (2003) Bosentan for the prevention of overcirculation-induced experimental pulmonary arterial hypertension. Circulation 107(9):1329\u20131335","journal-title":"Circulation"},{"issue":"3","key":"9_CR0009110","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1203\/pdr.0b013e318030d169","volume":"61","author":"B Rondelet","year":"2007","unstructured":"Rondelet B, Kerbaul F, Vivian GF, Hubloue I, Huez S, Fesler P et al (2007) Sitaxsentan for the prevention of experimental shunt-induced pulmonary hypertension. Pediatr Res 61(3):284\u2013288","journal-title":"Pediatr Res"},{"issue":"1","key":"9_CR0009111","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0022-3476(05)81552-5","volume":"123","author":"AA Rosenberg","year":"1993","unstructured":"Rosenberg AA, Kennaugh J, Koppenhafer SL, Loomis M, Chatfield BA, Abman SH (1993) Elevated immunoreactive endothelin-1 levels in newborn infants with persistent pulmonary hypertension. J Pediatr 123(1):109\u2013114","journal-title":"J Pediatr"},{"key":"9_CR0009112","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.jacc.2005.01.066","volume":"46","author":"EB Rosenzweig","year":"2005","unstructured":"Rosenzweig EB, Ivy DD, Widlitz A et al (2005) Effects of long-term bosentan in children with pulmonary arterial hypertension. J Am Coll Cardiol 46:697\u2013704","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"9_CR0009113","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1227\/00006123-199507000-00012","volume":"37","author":"S Roux","year":"1995","unstructured":"Roux S, L\u00f6ffler BM, Gray GA, Sprecher U, Clozel M, Clozel JP (1995) The role of endothelin in experimental cerebral vasospasm. Neurosurgery 37(1):78\u201385","journal-title":"Neurosurgery"},{"issue":"5","key":"9_CR0009114","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1378\/chest.120.5.1562","volume":"120","author":"C Rubens","year":"2001","unstructured":"Rubens C, Ewert R, Halank M, Wensel R, Orzechowski HD, Schultheiss HP et al (2001) Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest 120(5):1562\u20131569","journal-title":"Chest"},{"key":"9_CR0009115","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","volume":"346","author":"LJ Rubin","year":"2002","unstructured":"Rubin LJ, Badesch DB, Barst RJ et al (2002) Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346:896\u2013903","journal-title":"N Engl J Med"},{"issue":"2","key":"9_CR0009116","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/sj.bjp.0702315","volume":"126","author":"FD Russell","year":"1999","unstructured":"Russell FD, Davenport AP (1999) Secretory pathways in endothelin synthesis. Br J Pharmacol 126(2):391\u2013398","journal-title":"Br J Pharmacol"},{"issue":"5 Suppl 1","key":"9_CR0009117","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1097\/00005344-200036051-00031","volume":"36","author":"S Sakai","year":"2000","unstructured":"Sakai S, Miyauchi T, Hara J, Goto K, Yamaguchi I (2000) Hypotensive effect of endothelin-1 via endothelin-B-receptor pathway on pulmonary circulation is enhanced in rats with pulmonary hypertension. J Cardiovasc Pharmacol 36(5 Suppl 1):S95\u2013S98","journal-title":"J Cardiovasc Pharmacol"},{"issue":"5 Pt 1","key":"9_CR0009118","first-page":"L668","volume":"269","author":"K Sato","year":"1995","unstructured":"Sato K, Oka M, Hasunuma K, Ohnishi M, Kira S (1995) Effects of separate and combined ETA and ETB blockade on ET-1-induced constriction in perfused rat lungs. Am J Physiol 269(5 Pt 1):L668\u2013L672","journal-title":"Am J Physiol"},{"issue":"4 Pt 1","key":"9_CR0009119","first-page":"L571","volume":"276","author":"K Sato","year":"1999","unstructured":"Sato K, Rodman DM, McMurtry IF (1999) Hypoxia inhibits increased ETB receptor-mediated NO synthesis in hypertensive rat lungs. Am J Physiol 276(4 Pt 1):L571\u2013L581","journal-title":"Am J Physiol"},{"issue":"6","key":"9_CR0009120","doi-asserted-by":"crossref","first-page":"840","DOI":"10.3181\/00379727-231-2310840","volume":"231","author":"S Sauvageau","year":"2006","unstructured":"Sauvageau S, Thorin E, Caron A, Dupuis J (2006) Evaluation of endothelin-1-induced pulmonary vasoconstriction following myocardial infarction. Exp Biol Med (Maywood) 231(6):840\u2013846","journal-title":"Exp Biol Med (Maywood)"},{"issue":"5","key":"9_CR0009121","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1159\/000102534","volume":"44","author":"S Sauvageau","year":"2007","unstructured":"Sauvageau S, Thorin E, Caron A, Dupuis J (2007) Endothelin-1-induced pulmonary vasoreactivity is regulated by ET(A) and ET(B) receptor interactions. J Vasc Res 44(5):375\u2013381","journal-title":"J Vasc Res"},{"issue":"4","key":"9_CR0009122","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.pupt.2009.01.006","volume":"22","author":"S Sauvageau","year":"2009","unstructured":"Sauvageau S, Thorin E, Villeneuve L, Dupuis J (2009) Change in pharmacological effect of endothelin receptor antagonists in rats with pulmonary hypertension: role of ETB-receptor expression levels. Pulm Pharmacol Ther 22(4):311\u2013317","journal-title":"Pulm Pharmacol Ther"},{"issue":"4","key":"9_CR0009123","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1080\/00365510701673375","volume":"68","author":"S Schroll","year":"2008","unstructured":"Schroll S, Arzt M, Sebah D, Stoelcker B, Luchner A, Budweiser S et al (2008) Effects of selective and unselective endothelin-receptor antagonists on prostacyclin synthase gene expression in experimental pulmonary hypertension. Scand J Clin Lab Invest 68(4):270\u2013276","journal-title":"Scand J Clin Lab Invest"},{"issue":"1","key":"9_CR0009124","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.resp.2009.11.005","volume":"170","author":"S Schroll","year":"2010","unstructured":"Schroll S, Arzt M, Sebah D, Nuchterlein M, Blumberg F, Pfeifer M (2010) Improvement of bleomycin-induced pulmonary hypertension and pulmonary fibrosis by the endothelin receptor antagonist Bosentan. Respir Physiol Neurobiol 170(1):32\u201336","journal-title":"Respir Physiol Neurobiol"},{"issue":"2","key":"9_CR0009125","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0006-291X(91)91461-K","volume":"174","author":"WC Sessa","year":"1991","unstructured":"Sessa WC, Kaw S, Hecker M, Vane JR (1991) The biosynthesis of endothelin-1 by human polymorphonuclear leukocytes. Biochem Biophys Res Commun 174(2):613\u2013618","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"9_CR0009126","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1161\/01.HYP.30.5.1198","volume":"30","author":"M Shichiri","year":"1997","unstructured":"Shichiri M, Kato H, Marumo F, Hirata Y (1997) Endothelin-1 as an autocrine\/paracrine apoptosis survival factor for endothelial cells. Hypertension 30(5):1198\u20131203","journal-title":"Hypertension"},{"issue":"3","key":"9_CR0009127","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1046\/j.1523-1747.2001.01256.x","volume":"116","author":"X Shi-Wen","year":"2001","unstructured":"Shi-Wen X, Denton CP, Dashwood MR, Holmes AM, Bou-Gharios G, Pearson JD et al (2001) Fibroblast matrix gene expression and connective tissue remodeling: role of endothelin-1. J Invest Dermatol 116(3):417\u2013425","journal-title":"J Invest Dermatol"},{"issue":"6","key":"9_CR0009128","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1091\/mbc.e03-12-0902","volume":"15","author":"X Shi-Wen","year":"2004","unstructured":"Shi-Wen X, Chen Y, Denton CP, Eastwood M, Renzoni EA, Bou-Gharios G et al (2004) Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac\/phosphoinositide 3-kinase\/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts. Mol Biol Cell 15(6):2707\u20132719","journal-title":"Mol Biol Cell"},{"key":"9_CR0009156","first-page":"930","volume":"70","author":"PN Sidharta","year":"2010","unstructured":"Sidharta PN, Atsmon J, Dingemanse J (2010) Investigation of the effect of ketoconazole on the pharmacokinetics of macitentan in healthy male subjects. Br J Clin Pharmacol 70:930\u201331","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"9_CR0009129","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s00228-011-1043-2","volume":"67","author":"PN Sidharta","year":"2011","unstructured":"Sidharta PN, van Giersbergen PL, Halabi A, Dingemanse J (2011) Macitentan: entry-into-humans study with a new endothelin receptor antagonist. Eur J Clin Pharmacol 67(10):977\u2013984","journal-title":"Eur J Clin Pharmacol"},{"key":"9_CR0009157","first-page":"A4802","volume":"185","author":"PN Sidharta","year":"2012","unstructured":"Sidharta PN, van Giersbergen PLM, Wolzt M, Dingemanse J (2012a) Lack of clinically relevant pharmacokinetic interactions between the dual endothelin receptor antagonist macitentan and sildenafil in healthy subjects. Am J Respir Crit Care Med 185:A4802","journal-title":"Am J Respir Crit Care Med"},{"issue":"Suppl 56","key":"9_CR0009158","first-page":"166s","volume":"40","author":"PN Sidharta","year":"2012","unstructured":"Sidharta PN, van Giersbergen PLM, Wolzt M, Dingemanse J (2012b) Lack of relevant pharmacokinetic and pharmacodynamic interactions between the new dual endothelin receptor antagonist macitentan and warfarin in healthy subjects. Eur Respir J 40(Suppl 56):166s","journal-title":"Eur Respir J"},{"key":"9_CR0009130","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1164\/rccm.200404-445OC","volume":"170","author":"O Sitbon","year":"2004","unstructured":"Sitbon O, Gressin V, Speich R, Macdonald PS, Opravil M, Cooper DA, Fourme T, Humbert M, Delfraissy JF, Simonneau G (2004) Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 170:1212\u20131217","journal-title":"Am J Respir Crit Care Med"},{"key":"9_CR0009131","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1136\/thx.2005.040618","volume":"60","author":"O Sitbon","year":"2005","unstructured":"Sitbon O, McLaughlin VV, Badesch DB et al (2005) Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol. Thorax 60:1025\u20131030","journal-title":"Thorax"},{"issue":"6","key":"9_CR0009132","doi-asserted-by":"crossref","first-page":"L1013","DOI":"10.1152\/ajplung.00217.2009","volume":"297","author":"KR Stenmark","year":"2009","unstructured":"Stenmark KR, Meyrick B, Galie N, Mooi WJ, McMurtry IF (2009) Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol 297(6):L1013\u2013L1032","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"6","key":"9_CR0009133","doi-asserted-by":"crossref","first-page":"464","DOI":"10.7326\/0003-4819-114-6-464","volume":"114","author":"DJ Stewart","year":"1991","unstructured":"Stewart DJ, Levy RD, Cernacek P, Langleben D (1991) Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med 114(6):464\u2013469","journal-title":"Ann Intern Med"},{"issue":"2","key":"9_CR0009134","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1006\/pupt.2000.0237","volume":"13","author":"RG Tilton","year":"2000","unstructured":"Tilton RG, Munsch CL, Sherwood SJ, Chen SJ, Chen YF, Wu C et al (2000) Attenuation of pulmonary vascular hypertension and cardiac hypertrophy with sitaxsentan sodium, an orally active ET(A) receptor antagonist. Pulm Pharmacol Ther 13(2):87\u201397","journal-title":"Pulm Pharmacol Ther"},{"issue":"3","key":"9_CR0009135","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s11325-003-0111-y","volume":"7","author":"G Trakada","year":"2003","unstructured":"Trakada G, Nikolaou E, Pouli A, Tsiamita M, Spiropoulos K (2003) Endothelin-1 levels in interstitial lung disease patients during sleep. Sleep Breath 7(3):111\u2013118","journal-title":"Sleep Breath"},{"issue":"8","key":"9_CR0009136","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1124\/dmd.106.013615","volume":"35","author":"A Treiber","year":"2007","unstructured":"Treiber A, Schneiter R, Hausler S, Stieger B (2007) Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos 35(8):1400\u20131407","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"9_CR0009137","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.rmed.2009.02.016","volume":"103","author":"TK Trow","year":"2009","unstructured":"Trow TK, Taichman DB (2009) Endothelin receptor blockade in the management of pulmonary arterial hypertension: selective and dual antagonism. Respir Med 103(7):951\u2013962","journal-title":"Respir Med"},{"issue":"3","key":"9_CR0009138","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S0272-5231(05)70280-X","volume":"22","author":"RM Tuder","year":"2001","unstructured":"Tuder RM, Cool CD, Yeager M, Taraseviciene-Stewart L, Bull TM, Voelkel NF (2001) The pathobiology of pulmonary hypertension. Endothelium. Clin Chest Med 22(3):405\u2013418","journal-title":"Clin Chest Med"},{"issue":"Suppl 1","key":"9_CR0009139","doi-asserted-by":"crossref","first-page":"S453","DOI":"10.1097\/00005344-199800001-00129","volume":"31","author":"DC Underwood","year":"1998","unstructured":"Underwood DC, Bochnowicz S, Osborn RR, Louden CS, Hart TK, Ohlstein EH et al (1998) Chronic hypoxia-induced cardiopulmonary changes in three rat strains: inhibition by the endothelin receptor antagonist SB 217242. J Cardiovasc Pharmacol 31(Suppl 1):S453\u2013S455","journal-title":"J Cardiovasc Pharmacol"},{"issue":"10","key":"9_CR0009140","first-page":"1838","volume":"21","author":"R Vancheeswaran","year":"1994","unstructured":"Vancheeswaran R, Magoulas T, Efrat G, Wheeler-Jones C, Olsen I, Penny R et al (1994) Circulating endothelin-1 levels in systemic sclerosis subsets\u2013a marker of fibrosis or vascular dysfunction? J Rheumatol 21(10):1838\u20131844","journal-title":"J Rheumatol"},{"issue":"23","key":"9_CR0009141","doi-asserted-by":"crossref","first-page":"16066","DOI":"10.1016\/S0021-9258(18)41966-7","volume":"267","author":"OF Wagner","year":"1992","unstructured":"Wagner OF, Christ G, Wojta J, Vierhapper H, Parzer S, Nowotny PJ et al (1992) Polar secretion of endothelin-1 by cultured endothelial cells. J Biol Chem 267(23):16066\u201316068","journal-title":"J Biol Chem"},{"issue":"3","key":"9_CR0009142","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/j.1476-5381.1996.tb15446.x","volume":"118","author":"E Weitzberg","year":"1996","unstructured":"Weitzberg E, Hemsen A, Rudehill A, Modin A, Wanecek M, Lundberg JM (1996) Bosentan-improved cardiopulmonary vascular performance and increased plasma levels of endothelin-1 in porcine endotoxin shock. Br J Pharmacol 118(3):617\u2013626","journal-title":"Br J Pharmacol"},{"issue":"2","key":"9_CR0009143","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0022-3565(24)36446-8","volume":"280","author":"RN Willette","year":"1997","unstructured":"Willette RN, Ohlstein EH, Mitchell MP, Sauermelch CF, Beck GR, Luttmann MA et al (1997) Nonpeptide endothelin receptor antagonists. VIII: attentuation of acute hypoxia-induced pulmonary hypertension in the dog. J Pharmacol Exp Ther 280(2):695\u2013701","journal-title":"J Pharmacol Exp Ther"},{"key":"9_CR0009144","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/332411a0","volume":"332","author":"MH Yanagisawa","year":"1988","unstructured":"Yanagisawa MH, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y et al (1988) A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332:411\u2013415","journal-title":"Nature"},{"issue":"6","key":"9_CR0009145","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1161\/01.CIR.84.6.2280","volume":"84","author":"M Yoshibayashi","year":"1991","unstructured":"Yoshibayashi M, Nishioka K, Nakao K, Saito Y, Matsumura M, Ueda T et al (1991) Plasma endothelin concentrations in patients with pulmonary hypertension associated with congenital heart defects. Evidence for increased production of endothelin in pulmonary circulation. Circulation 84(6):2280\u20132285","journal-title":"Circulation"},{"issue":"2","key":"9_CR0009146","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/0006-291X(89)92679-X","volume":"161","author":"M Yoshizumi","year":"1989","unstructured":"Yoshizumi M, Kurihara H, Sugiyama T, Takaku F, Yanagisawa M, Masaki T et al (1989) Hemodynamic shear stress stimulates endothelin production by cultured endothelial cells. Biochem Biophys Res Commun 161(2):859\u2013864","journal-title":"Biochem Biophys Res Commun"},{"issue":"1\u20133","key":"9_CR0009147","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ejphar.2004.06.021","volume":"496","author":"H Yuyama","year":"2004","unstructured":"Yuyama H, Fujimori A, Sanagi M, Koakutsu A, Sudoh K, Sasamata M et al (2004) The orally active nonpeptide selective endothelin ETA receptor antagonist YM598 prevents and reverses the development of pulmonary hypertension in monocrotaline-treated rats. Eur J Pharmacol 496(1\u20133):129\u2013139","journal-title":"Eur J Pharmacol"},{"issue":"8724","key":"9_CR0009148","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/0140-6736(90)92766-B","volume":"336","author":"MR Zamora","year":"1990","unstructured":"Zamora MR, O\u2019Brien RF, Rutherford RB, Weil JV (1990) Serum endothelin-1 concentrations and cold provocation in primary Raynaud\u2019s phenomenon. Lancet 336(8724):1144\u20131147","journal-title":"Lancet"},{"issue":"Suppl 3","key":"9_CR0009149","doi-asserted-by":"crossref","first-page":"S336","DOI":"10.1097\/00005344-199506263-00101","volume":"26","author":"YD Zhao","year":"1995","unstructured":"Zhao YD, Springall DR, Hamid Q, Yacoub MH, Levene M, Polak JM (1995) Localization and characterization of endothelin-1 binding sites in the transplanted human lung. J Cardiovasc Pharmacol 26(Suppl 3):S336\u2013S340","journal-title":"J Cardiovasc Pharmacol"}],"container-title":["Handbook of Experimental Pharmacology","Pharmacotherapy of Pulmonary Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-642-38664-0_9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T07:43:48Z","timestamp":1749023028000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-642-38664-0_9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"ISBN":["9783642386633","9783642386640"],"references-count":157,"aliases":["10.1007\/978-3-662-45805-1_9"],"URL":"https:\/\/doi.org\/10.1007\/978-3-642-38664-0_9","relation":{},"ISSN":["0171-2004","1865-0325"],"issn-type":[{"value":"0171-2004","type":"print"},{"value":"1865-0325","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013]]},"assertion":[{"value":"6 August 2013","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}